Jefferies Financial Group Upgrades Pediatrix Medical Group (NYSE:MD) to Buy

Pediatrix Medical Group (NYSE:MD) was upgraded by equities research analysts at Jefferies Financial Group from a “hold” rating to a “buy” rating in a research report issued on Thursday, MarketBeat.com reports. The brokerage presently has a $14.00 price objective on the stock, up from their prior price objective of $8.00. Jefferies Financial Group’s price target would suggest a potential upside of 33.33% from the company’s current price.

A number of other research firms also recently commented on MD. UBS Group increased their price objective on shares of Pediatrix Medical Group from $9.00 to $10.50 and gave the company a “neutral” rating in a report on Friday, August 9th. Truist Financial increased their price target on Pediatrix Medical Group from $8.00 to $10.00 and gave the company a “hold” rating in a report on Thursday, August 15th. StockNews.com raised Pediatrix Medical Group from a “sell” rating to a “hold” rating in a research note on Wednesday, August 7th. Finally, Deutsche Bank Aktiengesellschaft upgraded Pediatrix Medical Group from a “sell” rating to a “hold” rating and set a $8.00 target price for the company in a report on Friday, June 7th. Five analysts have rated the stock with a hold rating and one has given a buy rating to the company. According to MarketBeat, Pediatrix Medical Group presently has a consensus rating of “Hold” and an average price target of $10.30.

Pediatrix Medical Group Stock Performance

Shares of MD stock opened at $10.50 on Thursday. The company has a market capitalization of $883.54 million, a P/E ratio of -12.35, a P/E/G ratio of 1.64 and a beta of 1.56. Pediatrix Medical Group has a 12-month low of $6.62 and a 12-month high of $13.01. The business’s 50 day moving average is $9.89 and its two-hundred day moving average is $8.85. The company has a current ratio of 1.38, a quick ratio of 1.38 and a debt-to-equity ratio of 0.87.

Pediatrix Medical Group (NYSE:MD) last released its quarterly earnings results on Tuesday, August 6th. The company reported $0.34 earnings per share for the quarter, topping the consensus estimate of $0.31 by $0.03. Pediatrix Medical Group had a negative net margin of 12.58% and a positive return on equity of 10.59%. The firm had revenue of $504.30 million during the quarter, compared to the consensus estimate of $505.49 million. During the same quarter in the prior year, the firm earned $0.37 EPS. The company’s revenue for the quarter was up .7% on a year-over-year basis. Analysts expect that Pediatrix Medical Group will post 1.18 EPS for the current fiscal year.

Insider Transactions at Pediatrix Medical Group

In other Pediatrix Medical Group news, CEO James D. Swift sold 11,100 shares of the business’s stock in a transaction that occurred on Friday, August 30th. The stock was sold at an average price of $10.79, for a total value of $119,769.00. Following the sale, the chief executive officer now owns 170,001 shares of the company’s stock, valued at $1,834,310.79. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. In other news, CFO C Marc Richards sold 32,562 shares of the stock in a transaction dated Friday, August 9th. The shares were sold at an average price of $10.08, for a total transaction of $328,224.96. Following the sale, the chief financial officer now owns 192,785 shares of the company’s stock, valued at $1,943,272.80. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO James D. Swift sold 11,100 shares of Pediatrix Medical Group stock in a transaction that occurred on Friday, August 30th. The shares were sold at an average price of $10.79, for a total transaction of $119,769.00. Following the completion of the transaction, the chief executive officer now owns 170,001 shares of the company’s stock, valued at approximately $1,834,310.79. The disclosure for this sale can be found here. In the last three months, insiders have sold 68,100 shares of company stock worth $701,889. 2.00% of the stock is currently owned by insiders.

Institutional Trading of Pediatrix Medical Group

Several hedge funds have recently modified their holdings of MD. nVerses Capital LLC acquired a new position in Pediatrix Medical Group during the 2nd quarter worth $31,000. Innealta Capital LLC purchased a new stake in shares of Pediatrix Medical Group during the second quarter worth approximately $33,000. Nisa Investment Advisors LLC raised its holdings in Pediatrix Medical Group by 47.2% in the second quarter. Nisa Investment Advisors LLC now owns 4,755 shares of the company’s stock valued at $36,000 after acquiring an additional 1,524 shares in the last quarter. Canada Pension Plan Investment Board purchased a new position in Pediatrix Medical Group in the second quarter worth approximately $72,000. Finally, Vanguard Personalized Indexing Management LLC acquired a new position in Pediatrix Medical Group during the 2nd quarter worth approximately $81,000. 97.71% of the stock is currently owned by institutional investors and hedge funds.

Pediatrix Medical Group Company Profile

Pediatrix Medical Group, Inc, together with its subsidiaries, provides newborn, maternal-fetal, pediatric cardiology, and other pediatric subspecialty care services in the United States. It offers neonatal care services, such as clinical care to babies born prematurely or with complications within specific units at hospitals through neonatal physician subspecialists, neonatal nurse practitioners, and other pediatric clinicians.